Galectin Therapeutics (GALT) vs Relmada Therapeutics (RLMD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Relmada Therapeutics (RLMD) has outperformed Galectin Therapeutics (GALT) over the past year, losing 38.6% versus a loss of 49.7%. Over five years, GALT leads with a +4.7% price change compared with -86.1% for RLMD. Relmada Therapeutics is the larger company by market cap ($279.5 million vs $271.4 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GALT | RLMD |
|---|---|---|
| Share price | $2.69 | $2.62 |
| Market cap | $271.35M | $279.54M |
| 1-day change | -4.27% | -15.76% |
| YTD return | -35.34% | -45.76% |
| 1-year return | -49.72% | -38.64% |
| 5-year return | +4.67% | -86.09% |
| EPS (TTM) | $-0.32 | $-0.73 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-30.84M | $-57.39M |
| 52-week high | $7.13 | $8.00 |
| 52-week low | $2.03 | $2.60 |
| Distance from 52-week high | -62.27% | -67.25% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +308.92% | +310.31% |
| Average volume | 252.31K | 1.45M |
| Shares outstanding | 100.88M | 106.69M |
| Employees | 9 | 17 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- RLMD has outperformed GALT by 11.1 percentage points over the past year.
About Galectin Therapeutics
GALT stock →Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in drug development to create new therapies for fibrotic disease and cancer. The company's lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in a Phase 2 clinical study in MASH patients with advanced fibrosis and a second Phase 2b clinical trial in MASH patients with compensated cirrhosis and portal hypertension.
Health Care · Biotechnology: Pharmaceutical Preparations · 9 employees
About Relmada Therapeutics
RLMD stock →Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 17 employees
GALT vs RLMD FAQ
Which is bigger, Galectin Therapeutics or Relmada Therapeutics?
Relmada Therapeutics (RLMD) is larger, with a market capitalization of $279.54M compared with $271.35M for Galectin Therapeutics (GALT).
Which stock has performed better over the past year, GALT or RLMD?
RLMD returned -38.64% over the past 12 months, compared with -49.72% for GALT (price return, excluding dividends). Past performance does not predict future results.
Are Galectin Therapeutics and Relmada Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.